While testicular nuclear receptor 4 (TR4) may promote prostate cancer (PCa) metastasis, its role in the clear cell renal cell carcinoma (ccRCC) remains unclear. Here we found a higher expression of TR4 in ccRCC tumors from patients with distant metastases than those from metastasis-free patients, suggesting TR4 may play positive roles in the ccRCC metastasis. Results from multiple in vitro ccRCC cell lines also confirmed TR4's positive roles in promoting ccRCC cell invasion/migration via altering the microRNA (miR-32-5p)/TR4/HGF/Met/MMP2-MMP9 signaling. Mechanism dissection revealed that miR-32-5p could suppress TR4 protein expression levels via direct binding to the 3 0 UTR of TR4 mRNA, and TR4 might then alter the HGF/Met signaling at the transcriptional level via direct binding to the TR4-response-elements (TR4RE) on the HGF promoter. Then the in vitro data also demonstrated the efficacy of Sunitinib, a currently used drug to treat ccRCC, could be increased after targeting this newly identified miR-32-5p/TR4/HGF/Met signaling. The preclinical study using the in vivo mouse model with xenografted ccRCC cells confirmed the in vitro cell lines data. Together, these findings suggest that TR4 is a key player to promote ccRCC metastasis and targeting this miR-32-5p/TR4/HGF/Met signaling with small molecules including TR4-shRNA or miR-32-5p may help to develop a new therapy to better suppress the ccRCC metastasis.
Renal cell carcinoma (RCC) is the most lethal urological tumor, constituting 2-3% of adult malignancies in the United States. 1 Clear cell RCC (ccRCC) is the most common histologic subtype and accounts for 70% of RCC. 2 Although a higher incidence of small renal masses is being detected, approximately one-third of patients still present with or will develop metastatic lesions during the course of the disease 3 and the detailed mechanism(s) of metastasis remain unclear.
Testicular nuclear receptor 4 (TR4), also known as NR2C2 (nuclear receptor subfamily 2, group C, member 2), is a transcriptional factor and a member of the nuclear receptor family. [4] [5] [6] Earlier studies from TR4 knockout (TR4KO) mice revealed that TR4 might play important roles in fertility, bone formation, neural development and metabolism. [7] [8] [9] [10] [11] Recent studies also found TR4 might play a negative role to suppress prostate cancer (PCa) initiation, yet played a positive role to promote PCa metastasis, [12] [13] [14] which is opposite the androgen receptor that promotes PCa initiation and suppresses PCa metastases. 15 These contrasting results prompted us to investigate TR4 potential impacts on the ccRCC progression.
The microRNAs (miRNAs) are a class of short (19-22 nucleotides) , noncoding RNA sequences that can negatively regulate gene expression via interacting with the 3 0 untranslated region (3 0 UTR) of target mRNAs 16 or positively regulate gene expression via interacting with the 5 0 promoter region. 17 Studies have documented the role of miRNAs in cellular proliferation and invasion in a variety of tumors [18] [19] [20] including RCC. [21] [22] [23] Whether TR4 may also function in the network of miRNAs to influence the ccRCC progression, however, remains unclear.
Here we report that TR4 might play a positive role in promoting ccRCC metastasis via upregulating the HGF/Met signaling. We also demonstrated miR-32-5p might suppress ccRCC metastasis via suppressing the TR4/HGF/Met signaling.
Materials and Methods
Cell culture ACHN, OSRC-2 and SW839 cell lines were purchased from the American Type Culture Collection (Rockville, MD) in December of 2009. After cells were received, the cell lines were frozen in liquid N2 after the first 3 passages with 50 ampules of cell stock. After an ampule is thawed, cells are used for the designed experiments within 15 passages. All cell lines were cultured in Dulbecco's Modified Eagle's Medium (Invitrogen, Grand Island, NY, USA) supplemented with 10% FBS (v/v), penicillin (25 units/ml), streptomycin (25 lg/ml), 1% L-glutamine and 10% fetal bovine serum (FBS). All cell lines were cultured in a 5% (v/v) CO 2 humidified incubator at 378C.
Cell invasion assay
The invasion capability of RCC cells was determined using the Matrigel-coated Transwell assay. Briefly, cells were harvested and seeded at 5 3 10 4 cells/well with serum-free media into the upper chambers coated with Matrigel (Trivigen, #3500-096-K). Then 750 ll 10% FCS media was placed in the lower chambers for 24 hr incubation at 378C in 5% (v/ v) CO 2 incubator. The cells invaded into the matrigel were fixed by 4% paraformaldehyde and stained with 0.1% (w/v) crystal violet. The invaded cells were counted in ten randomly chosen microscope fields (1003) in each experiment for quantification. Each sample was run in triplicate and in multiple experiments.
3D invasion assay
The 3D invasion assay was performed as previously described. 24 Briefly, 1 310 4 cells were suspended in 200 ml media containing 1% Matrigel and then plated into the previously prepared collagen/Matrigel mixture coated plates. Media was replenished every 3 days for 2 weeks and then spheres and protrusions numbers were recorded under microscope.
Wound healing assay
We seeded cells into 6-well tissue culture plates at a density that after 24 hr of growth, they should reach 70-80% confluence as a monolayer. We then gently and slowly scratched the monolayer with a sterile 200 ll pipette tip across the center of the well. After scratching, we gently washed the well twice with media to remove the detached cells and replenished the well with fresh media. We then incubated the cells for an additional 24 hr, washed the cells twice with 13 PBS and then took photos. The percentage of decreased wound width was compared between the control group and experimental group.
RNA extraction and qRT-PCR analysis
For RNA extraction, total RNAs were isolated using Trizol reagent (Invitrogen). One microgram of total RNA was subjected to reverse transcription using Superscript III transcriptase (Invitrogen). Quantitative real-time PCR (qRT-PCR) was conducted using a Bio-Rad CFX96 system with SYBR green to determine the mRNA expression level of a gene of interest. Expression levels were normalized to the expression of GAPDH RNA. The miRNAs were isolated using PureLink V R miRNA kit. Briefly, 50 ng small RNAs were processed for poly A addition by adding 1 unit of polymerase with 1 mM ATP in 13 RT buffer at 378C for 10 min in 10 ll volume, then heat inactivated at 958C for 2 min. We then added 50 mmol anchor primer to 12.5 ll, and incubated at 658C for 5 min. For the last step of cDNA synthesis, we added 2 ll 53 RT buffer, 2 ll 10 mM dNTP, 1 ll reverse transcriptase to total 20 ll and incubated at 428C for 1 hr. Quantitative realtime PCR (qPCR) expression levels were normalized to the expression of 5s RNA and/or U6.
Immunoblot analysis
Cells were lysed in RIPA buffer and proteins (30 mg) were separated on 8-10% SDS/PAGE gel and then transferred onto PVDF membranes (Millipore, Billerica, MA, USA). After blocking membranes, they were incubated with appropriate dilutions of specific primary antibodies, including TR4 
Chromatin immunoprecipitation assay (ChIP)
Cell lysates were precleared sequentially with normal rabbit IgG (sc-2027, Santa Cruz Biotechnology) and protein Aagarose. Then 2.0 mg of anti-TR4 antibody (ab109301, Abcam) was added to the cell lysates and incubated at 48C overnight. For the negative control, IgG was used in the reaction. Specific primer sets was designed to amplify a target sequence within human HGF promoter and PCR products were identified by agarose gel electrophoresis.
Renal capsule implantation
OSRC-2 cells expressing Luciferase and expressing pLKO.1-shTR4, pLKO.1-scramble, or pLVTHM-miR-32-5p (2 3 10 6 ) were injected into the left renal capsule of 6-week-old male athymic nude mice (NCI) (n 5 8 mice per group). We checked the body weights every week and used the noninvasive in vivo imaging system (IVIS) every 2 weeks to monitor the tumor/metastasis growth. After 8 weeks, mice were sacrificed, and tumors were excised. Studies on animals were conducted with approval from the Animal Research Ethics Committee of the University of Rochester Medical Center.
H&E and immunohistochemical (IHC) staining
Tissues were fixed in 10% (v/v) formaldehyde in PBS, embedded in paraffin, cut into 5 lm sections and used for H&E staining and IHC staining with specific primary antibodies against TR4 and HGF (AP1724b, One World Lab). To enhance antigen exposure, the slides were treated with 13 EDTA at 988C for 10 min for antigen retrieval. The slides were incubated with endogenous peroxidase blocking solution, and then were incubated with the primary antibody at 48C overnight. After rinsing with Tris-buffered saline, the slides were incubated for 45 min with biotin-conjugated secondary antibody, washed, and then incubated with enzyme conjugate horseradish peroxidase (HRP)-streptavidin. Freshly prepared DAB (Zymed, South San Francisco, CA, U.S.A.) was used as the substrate to detect HRP. Finally, slides were counter-stained with hematoxylin and mounted with aqueous mounting media. Positive cells were calculated as the number of immunopositive cells 3 100% divided by total number of cells/field in 10 random fields at 4003 magnification.
Statistical analysis
Data were expressed as mean 6 SEM from at least 3 independent experiments. Statistical analyses involved paired t test with SPSS 17.0 (SPSS Inc., Chicago, IL). p <0.05 was considered statistically significant.
Results

Higher expression of TR4 is correlated with ccRCC metastasis
The higher TR4 expression has been found in PCa patients with a higher Gleason score. 12, 13 The linkage of TR4 expression in the different stages of ccRCC, however, remains unclear. We first applied the IHC staining with TR4 antibody to examine the TR4 expression in human clinical ccRCC samples and found higher TR4 expression in ccRCC from patients with metastases (Supporting Information, Table 1 shows the Clinical parameters for the ccRCC patients) than those from metastasis-free patients (Fig. 1a) , suggesting TR4 may play positive roles to promote the ccRCC metastasis. Results from database analysis in the TCGA (TCGA website: http://cancergenome.nih.gov/) of 606 primary ccRCC samples also revealed that patients with higher TR4 expression had significantly lower recurrence-free survival (HR 5 1.587) than patients with lower TR4 expression (Fig. 1b) . Furthermore, we found that patients with higher TR4 expression had lower overall survival (HR 5 1.397) than patients with lower TR4 expression (Supporting Information, Fig. S2a ), but with less significance.
To confirm these clinical results in the in vitro multiple ccRCC cell lines, we first assayed the TR4 expression in various ccRCC cells and results using Transwell assay revealed the higher TR4 expression with higher invasion capacities in 786-O, A498, OSRC-2 and SW839 cells compared to other ccRCC cells including Caki-2, ACHN and SN12-PM6 (Figs. 1c and 1d) with C4-2 cells as a positive control.
Together, results from Figures 1a-1d and Supporting Information, Figure S2a suggest that TR4 may play a positive role to promote the ccRCC metastasis.
TR4 promotes RCC cells invasion and migration in vitro
We then applied the Matrigel-coated Transwell invasion assay 25 to confirm our initial findings via altering the TR4 expression using a lentiviral system in both VHL-wild type ACHN and VHL-mutant OSRC-2 cells. The results revealed that adding TR4-cDNA led to significantly increase the invasion capacity of the ACHN cells that have lower endogenous TR4 ( Fig. 2a) , and knocking-down TR4 could significantly decrease the invasion capacity of the OSRC-2 cells that have higher endogenous TR4 (Fig. 2b) . Similar results were obtained when we replaced OSRC-2 cells with the ccRCC SW839 cells ( Supporting Information, Fig. S3a) .
We also replaced the Matrigel-coated Transwell invasion assay with the 3 D invasion assay to confirm the above findings and results revealed that adding TR4-cDNA increased the cell invasion in ACHN cells (Fig. 2c) and knocking-down TR4 with TR4-shRNA decreased the cell invasion in OSRC-2 cells (Fig. 2d) . Finally, results from wound healing assays also indicated that adding TR4-cDNA increased the cell migration in ACHN cells (Fig. 2e) , and knocking-down TR4 decreased the cell migration in OSRC-2 and SW839 cells ( the metastasis in PCa cells, 12, 13 we then analyzed the expression of CCL2, TGFbR2 and p-SMAD3 after manipulating the TR4 expression in ACHN and OSRC-2 cells. The results revealed that altering TR4 (either adding TR4-cDNA or knocking-down with shTR4) led to little impact on these three proteins expression ( Supporting Information, Fig. S4a ).
We then analyzed many reported RCC metastasisassociated genes mRNA expressions and found some were altered after manipulating the TR4 expression. Among these genes, we found HGF mRNA expression was significantly altered (Fig. 3a) , and results from the NCBI GEO DataSets (GEO GSE29609) analysis of the ccRCC sample array also revealed a significant positive correlation (r 5 0.3632, p 5 0.0115) between the TR4 expression and HGF expression in 39 ccRCC specimens (Fig. 3b) .
We then confirmed the above results at the protein level showing adding TR4-cDNA led to increase the expression of HGF and phospho-Met with unchanged total-Met expression in ACHN cells (Fig. 3c) . In contrast, knocking-down TR4 with TR4-shRNA led to significantly decreased HGF and phospho-Met with unchanged total-Met expression in OSRC-2 cells (Fig. 3c) .
As early studies indicated that HGF/Met signaling might promote cancer cell migration and invasion via elevating MMP2/MMP9 expression, 26, 27 we also assayed these potential downstream signals, and results revealed that adding TR4-cDNA led to increase the expression of MMP2 and MMP9 in ACHN cells and knocking-down TR4 with TR4-shRNA suppressed the expression of MMP2 and MMP9 in OSRC-2 cells (Fig. 3c) . Similar results were also obtained in SW839 Fig. S4b) .
Finally, using interruption approaches with Met kinase inhibitor SU11274 (5 lmol/L) for the cell invasion assay, we found Met kinase inhibitor could reverse/block the TR4-enhanced ccRCC cells invasion in ACHN and OSRC-2 cells (Fig. 3d) .
Together, results from Figures 3a-3d and Supporting Information, Figures S4a and S4b suggest that the TR4 may function via altering HGF/Met/MMP2-MMP9 signaling to promote the ccRCC cells invasion.
Mechanism dissection of how TR4 upregulates HGF expression: via transcriptional regulation
To dissect the mechanism how TR4 could modulate the expression of HGF at the transcriptional level, we first applied the JASPER database to search for potential TR4 response elements (TR4REs) on the 2 kb HGF 5 0 promoter region (Fig.  3e) , and found two putative TR4REs (2146221448; 23452331) (Fig. 3f) . Results from the chromatin immunoprecipitation (ChIP) assay revealed that TR4 could bind to the TR4RE located 331-345 bp from the transcription start site of HGF in ACHN cells (Fig. 3g) . We also found that TR4 could bind to this region in the OSCR-2 cells and knocking-down TR4 could decrease this binding (Fig. 3h) .
We then constructed the HGF promoter luciferase reporter by inserting a 1 kb 5 0 promoter region of HGF containing either wild type or mutated TR4RE into the pGL3 luciferase backbone (Fig. 3i) , and results revealed that adding TR4-cDNA significantly increased luciferase activity in ACHN and OSRC-2 cells with wild type but not mutated TR4RE (Figs. 3j and 3k) .
Together, results from Figures 3e-3k suggest that TR4 can increase HGF expression at the transcriptional level via binding to the TR4RE located on its 5 0 promoter region.
Targeting the TR4 with miR-32-5p
To search for the small molecules that can target this newly identified TR4/HGF/Met/MMP2-MMP9 signaling, we focused on the miRNAs as recent studies indicated that miRNAs might function as key regulators to alter the cancer progression, 28 and some selective miRNAs have been linked to the ccRCC cell invasion. [21] [22] [23] 29 Results from multiple databases (TargetScan, miRDB and microRNA.org) analyses also revealed some potential candidate miRNAs that might suppress TR4 expression via targeting its 3 0 UTR. We then focused on 6 miRNAs whose expression were downregulated in patients with distant metastases based on the data from Wotschofsky Z's microarray. 28 Experiments testing the effects of these miRNAs on TR4 expression found that altering the miR-32-5p led to decrease TR4 expression in both ccRCC cell lines (Fig. 4a) . Importantly, treating with miR-32-5p inhibitor (5 nmol/L, MIN0000090, Qiagen) resulted in an increase of TR4 mRNA in ACHN cells and a decreased TR4 mRNA expression after adding the miR-32-5p in OSRC-2 and SW839 cells (Supporting Information, Figs. S5a-S5c).
Results from a clinical sample survey also revealed a significant negative correlation (r 5 20.5521, p 5 0.0142), using the Pearson correlation coefficient, between the expression of miR-32-5p and TR4 in 19 ccRCC patient specimens (Fig.  4b) , with lower miR-32-5p expression linked to the higher TR4 mRNA expression, and vice versa (Fig. 4c) . Similar results also occurred showing a negative correlation between miR-32-5p and TR4 expression in multiple ccRCC cell lines (Fig. 4d) .
A further analysis of Wotschofsky Z's miRNA microarray raw data in GEO DataSets (GEO GSE37989) indicated that miR-32-5p was downregulated in ccRCC tissue samples from patients with distant metastases compared to those from metastasis-free patients (Fig. 4e) . Results from a database from TCGA (TCGA website: http://cancergenome.nih.gov/) that included miRNA expression data from 326 primary ccRCC samples also revealed that patients with a higher miR-32 expression had significantly higher recurrence-free survival (HR 5 0.5628) than patients with lower miR-32 expression (Fig. 4f) . Furthermore, we also found that patients with higher miR-32 expression had higher overall survival (HR 5 0.8254) than patients with lower miR-32 expression (Supporting Information, Fig. S2b ), but with less significant results.
We also applied the Matrigel-coated Transwell invasion assay to confirm the consequence of miR-32-5p expression, and results revealed that treating with miR-32-5p inhibitor significantly promoted ACHN cells invasion (Fig. 4g) and addition of miR-32-5p via lentiviral system markedly suppressed ccRCC cells invasion in OSRC-2 ( Fig. 4h ) and SW839 cells ( Supporting Information, Fig. S5d ). Wound healing assays also indicated that knocking-down miR-32-5p promoted cell invasion in ACHN cells (Fig. 4i) and adding miR-32-5p decreased cell migration in OSRC-2 ( Fig. 4j ) and SW839 cells ( Supporting Information, Fig. S5e) .
Together, results from Figures 4a-4j and Supporting Information, Figures S2b and S5a-S5e demonstrate that miR-32-5p is linked to the ccRCC metastasis and is the upstream of TR4 that can suppress the TR4 expression to inhibit the ccRCC cell invasion and migration.
The miR-32-5p functions through altering the TR4/HGF/ Met/MMP2-MMP9 signaling to suppress the ccRCC metastasis
To further link the miR-32-5p-suppressed TR4 to the TR4/ HGF/Met/MMP2-MMP9 signaling for altering the ccRCC metastasis, we first confirmed that treating with miR-32-5p inhibitor increased the expression of TR4, HGF and phosphorylated-Met (phospho-Met) expression with little impact on the total-Met expression in ACHN cells (Fig. 5a ) and adding miR-32-5p decreased the expression of TR4, HGF and phosphorylated-Met in OSRC-2 ( Fig. 5a ) and SW839 cells ( Supporting Information, Fig. S6a ). As expected, altering the miR-32-5p expression also led to regulate the gene expression (Fig. 5a) .
Importantly, using the rescue assay, we found knockingdown TR4 could partially block the cell invasion induced by miR-32-5p inhibitor in ACHN cells and adding TR4-cDNA could partially reverse the miR-32-5p-suppressed cell invasion in OSRC-2 cells (Fig. 5b) . Knocking down TR4 could also partially block the HGF and phospho-Met expression induced by miR-32-5p inhibitor in ACHN cells (Fig. 5c ) and adding TR4 could partially reverse the miR-32-5p-suppressed HGF and phospho-Met expression in OSRC-2 cells, with little influence on the total Met expression in both cells (Fig. 5d) .
Together, results from Figures 5a-5d and Supporting Information, Figure S6a suggest that miR-32-5p suppressed ccRCC cells invasion via altering the TR4/HGF/Met/MMP2-MMP9 signaling.
Mechanism dissection of how miR-32-5p decreases TR4 expression: via 3 0 UTR regulation
To further dissect the mechanism how miR-32-5p can regulate TR4 expression, we focused on the 3 0 UTR regulation, as early studies indicated that miRNAs could negatively regulate gene expression via interacting with the 3 0 UTR of target mRNAs 16 or positively regulate gene expression via interacting with the 5 0 promoter region. 17 We first identified one predicted miRNA-responsive-element that matched the seed sequence of miR-32-5p in the 3 0 UTR of TR4 gene (Fig. 5e) . We then inserted a 959 bp fragment from the TR4 3 0 UTR that contains the predicted miR-32-5p target site (or its mutation) into a dual-luciferase reporter backbone psiCHECK TM -2 (Fig. 5e) . As expected, the luciferase assay results revealed that treating with miR-32-5p inhibitor significantly increased luciferase activity in the ACHN cells (Fig. 5f) , and adding miR-32-5p markedly decreased luciferase activity in OSRC-2 cells transfected with wild type TR4 3 0 UTR, but not the mutant TR4 3 0 UTR (Fig.  5g) . Similar results were also obtained when we replaced OSRC-2 with SW839 cells (Supporting Information, Fig. S6b) .
Together, results from Figures 5e-5g and Supporting Information, Figure S6b suggest that miR-32-5p can directly and specifically regulate TR4 expression through binding to its 3 0 UTR.
Preclinical study using in vivo mouse model to confirm TR4 and miR-32-5p roles in the ccRCC metastasis
To confirm all the above in vitro cell lines data in the in vivo mouse model, we prepared orthotopic xenografts of OSRC-2 cells with luciferase expression and with/without shTR4 or miR-32-5p. After 8 weeks, a dramatic decrease of metastatic luciferase signal using the IVIS was found in mice injected with the OSCR-2-Luc-shTR4 cells and OSCR-2-Luc-miR-32-5p cells group compared to the OSCR-2-Luc control group (Fig. 6a) . Similar reduced metastatic foci in lung, spleen, liver and right kidney using H&E staining or IVIS were also found in OSCR-2-Luc-shTR4 group and OSCR-2-Luc-miR-32-5p group compared to the OSCR-2-Luc control group (Figs. 6b and 6c). The OSCR-2-Luc control group also had relatively higher rates of lung metastasis and more metastasis foci than the OSCR-2-Luc-shTR4 group and OSCR-2-Luc-miR-32-5p group (Figs. 6d and 6e) . Importantly, our IHC staining from these ccRCC xenografts also demonstrated that OSCR-2-LucmiR-32-5p tumors had a lower TR4 expression compared to tumors from the OSCR-2-Luc control group and the tumors from the OSCR-2-Luc miR-32-5p group. Also the OSCR-2-Luc-shTR4 group had a lower HGF expression compared to those from the OSCR-2-Luc control group. Both of these observations were consistent with our in vitro findings (Fig.  6f) . Together, results from preclinical studies using the in vivo mouse model (Figs. 6a-6f ) demonstrate that targeting this newly identified miR-32-5p/TR4/HGF/Met signaling with small molecules including the TR4-shRNA or miR-32-5p can suppress ccRCC metastasis.
Sunitinib suppresses ccRCC metastasis via altering the miR-32-5p-TR4 signal Interestingly, we found this newly identified miR-32-5p/TR4/ HGF/Met signaling might also impact the current Sunitinibchemotherapy to suppress the ccRCC. We first found that treating with Sunitinib could increase miR-32-5p expression (Figs. 7a-7c ) and decrease the TR4 protein (Fig. 7d) in a dose-dependent manner in ACHN, OSRC-2 and SW839 cells. Importantly, suppressing miR-32-5p with the miR-32-5p inhibitor led to partially reverse the Sunitinib-suppressed ccRCC cell invasion in both ACHN and OSRC-2 cells (Fig.  7e) , suggesting that targeting this miR-32-5p/TR4/HGF/Met signaling pathway can also alter the efficacy of Sunitinibsuppressed ccRCC cell invasion.
Discussion
The ccRCC is a highly metastatic tumor that may resist most chemotherapies and radiotherapy, and anti-VEGF targeted therapy remains as the first line therapy for metastatic ccRCC even though it may only last for 6-15 months. 30 Therefore, a new therapy to better suppress ccRCC metastasis is much needed to extend patients survival. We provided the first preclinical evidence showing targeting the newly identified miR-32-5p/TR4/HGF/Met signaling with small molecules including miR-32-5p or TR4-shRNA could further suppress the ccRCC metastasis. This is clinically significant and may help to develop a new therapy to better suppress ccRCC metastasis.
Interestingly, mechanism dissection found that TR4 might play a positive role to promote RCC metastasis via altering the HGF/Met/MMP2-MMP9 signaling, which is opposite the early studies showing TR4 might play negative roles to suppress PCa metastasis via altering CCL2/CCR signaling. 12 The precise reasons why TR4 utilizes different signaling pathways to influence these two urological tumors' metastasis is not clear.
Inappropriate activation of HGF/Met signaling 31 may function via autocrine and paracrine manners to impact the tumor growth, angiogenesis and metastasis in various types of cancers including ccRCC. 32, 33 While our results from ccRCC cell lines suggest that the HGF/Met signaling may function through autocrine signaling to promote ccRCC cell invasion/migration, it is possible that upon activation via phosphorylation or gene amplification of Met, the HGF/Met signaling can also function through a paracrine axis involving cancer-associated fibroblasts and endothelium 34, 35 to influence the ccRCC metastasis. Our results confirmed that HGFinduced phosphorylation of Met and not amplification of Met to mediate the TR4-induced ccRCC metastasis. Early studies identified some compounds, including polyunsaturated fatty acids and the thiazolidinedione, 36,37 might function as TR4 ligands/activators. We found here that miRNAs might also be able to alter the TR4 expression, which might have the potential to be developed as a new therapy to better suppress the ccRCC. A growing body of evidence indicates that the miRNAs might play a vital role in altering gene expression and be used as diagnostic and therapeutic agents in clinical trials. 38 Our finding that miR-32-5p might function as an metastasis suppressor in ccRCC via directly targeting the 3 0 UTR of TR4 to suppress the TR4-HGF/Met signaling is interesting as earlier studies suggested miR-32-5p could also function as an oncogene to promote PCa 39 and colorectal carcinoma 40 progression. In summary, TR4 may upregulate HGF/Met signaling to promote ccRCC metastasis and miR-32-5p may target TR4/ HGF/Met signaling to suppress ccRCC metastasis. Using small molecules including TR4-shRNA or miR-32-5p may help to potentially develop new therapies to better suppress the ccRCC metastasis. 
